Compare Extra Space Storage, Inc. (EXR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs TG Therapeutics Inc — how do they compare? Extra Space Storage, Inc. trades at $134.5 (market cap $28.12B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Extra Space Storage, Inc. is far larger — about 3.4× TG Therapeutics Inc's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and TG Therapeutics Inc for 16 Days on average.
| EXR | TGTX | |
|---|---|---|
Market Cap | $28.12B | $8.16B |
Volume | 2,595,579 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $59.06 |
52-Week Low | $126.67 | $26.94 |
Typical Hold Time | 109 Days | 16 Days |
Enterprise Value | $41.84B | $8.37B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $134.22, up 1.91% today, with a bearish technical signal but strong fundamentals including a 27.79% net income margin and consistent earnings beats. The company reported $3.38B in 2025 revenue, with a P/E of 29.39 and a consensus price target of $158.33. Recent news highlights executive leadership transition and a Q3 2026 earnings call scheduled for October 27, 2026.
Outlook is mixed: analyst consensus is evenly split between Buy and Hold, with upside potential from operational strength, but risks include high debt levels and bearish technical indicators. The stock offers a dividend yield supported by stable cash flows, though macroeconomic sensitivity and valuation premiums warrant caution.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
